Security key
64136E102
Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP)
CUSIP: 64136E102
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.00001 par value per share
- Shares outstanding
- 5,420,049
- Total 13F shares
- 1,465,999
- Share change
- +1,270,661
- Total reported value
- $5,687,252
- Price per share
- $3.88
- Number of holders
- 21
- Value change
- +$4,548,427
- Number of buys
- 18
- Number of sells
- 4
Report period
Q4 2025
Institutions
21
Top holders
10
NEUP full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Neuphoria Therapeutics Inc. SEC filings
Neuphoria Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 64136E102
Recent filing periods:
Top shareholders of NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP |
3/4/5
13D/G
|
10%+ Owner |
16%
from 13D/G
|
875,328
|
$10,381,390 | — | 21 Oct 2025 | |
| Shay Capital LLC |
13D/G
|
— |
7.3%
|
171,629
|
$2,035,520 | $0 | 24 Oct 2025 | |
| Coastlands Capital LP |
13D/G
|
— |
5.1%
|
120,000
|
$1,423,200 | $0 | 05 Nov 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
1,033,796
|
$5,365,401 | $0 | 31 Dec 2024 | |
| Apeiron Investment Group Ltd. |
13D/G
|
— |
4.5%
|
72,618
|
$376,887 | $0 | 24 Jan 2025 | |
| Baselake Partners, LP |
13D/G
|
— |
4.1%
|
222,222
|
$862,110 | $0 | 31 Dec 2025 | |
| AdvisorShares Investments LLC |
13F
|
Company |
1.1%
|
58,563
|
$690,458 | — | 30 Sep 2025 | |
| Prosperity Wealth Management, Inc. |
13F
|
Company |
0.55%
|
29,825
|
$351,637 | — | 30 Sep 2025 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.4%
|
21,452
|
$252,919 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.39%
|
20,950
|
$247,001 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.34%
|
18,329
|
$216,099 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.29%
|
15,669
|
$184,738 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
12,978
|
$153,010 | — | 30 Sep 2025 | |
| Merck & Co., Inc. |
13F
|
Company |
0.18%
|
10,027
|
$118,218 | — | 30 Sep 2025 | |
| Persistent Asset Partners Ltd |
13F
|
Company |
0.09%
|
4,908
|
$57,865 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.04%
|
2,168
|
$25,560 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
410
|
$4,834 | — | 30 Sep 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0%
|
33
|
$389 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
17
|
$201 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
7
|
$83 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
0%
|
2
|
$24 | — | 30 Sep 2025 | |
| Spyros Papapetropoulos |
3/4/5
|
President and CEO, Director |
—
class O/S missing
|
74,088
|
$612,707 | — | 27 Aug 2025 |
Institutional Holders of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) as of Q4 2025
As of 31 Dec 2025,
Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,465,999 shares.
The largest 10 holders included
Lynx1 Capital Management LP, Shay Capital LLC, AdvisorShares Investments LLC, DIADEMA PARTNERS LP, Ikarian Capital, LLC, ADAR1 Capital Management, LLC, FNY Investment Advisers, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, and JANE STREET GROUP, LLC.
This page lists
21
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
15
Q4 2025 holders
21
Holder diff
6
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.